SCHEMBL4501740

SCHEMBL4501740

O=c1[nH]c(C2CN(c3nnc(-c4ccccc4)[nH]3)C2)nc2c1cnn2-c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.52
TSHR P16473 2/20 0.52
TYK2 P29597 1/20 0.52
HPGD P15428 1/20 0.52
PDE5A O76074 6/20 0.47
CSNK2A2 P19784 2/20 0.46
CSNK2B P67870 2/20 0.46
CSNK2A1 P68400 2/20 0.46
L3MBTL1 Q9Y468 2/20 0.44
TP53 P04637 1/20 0.44
KMT2A Q03164 2/20 0.43
POLB P06746 2/20 0.43
HSD17B10 Q99714 2/20 0.43
KDM4E B2RXH2 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
MEN1 O00255 1/20 0.42
HTT P42858 1/20 0.42
MAPK1 P28482 1/20 0.41
MAPT P10636 1/20 0.41
CREBBP Q92793 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4591180 0.85 TYK2 (0.62) ALDH1A1TSHRTYK2HPGDPDE5A
SCHEMBL4501728 0.84 PDE9A (0.54)
SCHEMBL4512357 0.81 KMT2A (0.53) ALDH1A1TSHRTYK2HPGDPDE5A
SCHEMBL4497280 0.81 TYK2 (0.50) ALDH1A1TSHRTYK2HPGDPDE5A
SCHEMBL4513652 0.79 TYK2 (0.50) ALDH1A1TSHRTYK2HPGDPDE5A
SCHEMBL4510202 0.78 TYK2 (0.58) ALDH1A1TSHRTYK2HPGDPDE5A
SCHEMBL4498181 0.78 TYK2 (0.56) ALDH1A1TSHRTYK2HPGDPDE5A
SCHEMBL4510623 0.77 TYK2 (0.55) ALDH1A1TSHRTYK2HPGDPDE5A
Hydrochloric Acid SCHEMBL4511418 0.77 TYK2 (0.62) ALDH1A1TSHRTYK2HPGDPDE5A
SCHEMBL17506173 0.77 TYK2 (0.57) ALDH1A1TSHRTYK2HPGDPDE5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008055959-A1 NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES GALAPAGOS N.V. (BE) 2008-05-15 WO claimed
US-11166956-B2 Combinations of PDE1 inhibitors and NEP inhibitors INTRA-CELLULAR THERAPIES, INC. (US) 2021-11-09 US disclosed
US-20190275046-A1 NOVEL COMBINATION INTRA-CELLULAR THERAPIES, INC. (US) 2019-09-12 US disclosed
US-10285992-B2 Combinations of PDE1 inhibitors and NEP inhibitors and associated methods INTRA-CELLULAR THERAPIES, INC. (US) 2019-05-14 US disclosed
US-20160038494-A1 NOVEL COMBINATION INTRA-CELLULAR THERAPIES, INC. 2016-02-11 US disclosed
US-20090137549-A1 Novel compounds useful for the treatment of degenerative & inflamatory diseases GALAPAGOS NV (BE) 2009-05-28 US disclosed
WO-2008055959-A1 NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES GALAPAGOS N.V. (BE) 2008-05-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160038494-A1 NOVEL COMBINATION PDE5A, PDE2A, PDE3A ALDH1A1 1873/4885TSHR 3757/4885TYK2 4707/4885
US-10285992-B2 Combinations of PDE1 inhibitors and NEP inhibitors and associated methods PDE5A, PDE3A, PDE2A ALDH1A1 1254/4885TSHR 3845/4885TYK2 4749/4885
US-20090137549-A1 Novel compounds useful for the treatment of degenerative & inflamatory diseases PDE4A, PDE7B, PDE4B ALDH1A1 240/4885TSHR 4657/4885TYK2 3816/4885
US-20190275046-A1 NOVEL COMBINATION PDE5A, PDE2A, PDE3A ALDH1A1 1873/4885TSHR 3757/4885TYK2 4707/4885
US-11166956-B2 Combinations of PDE1 inhibitors and NEP inhibitors PDE5A, ECE1, PDE3A ALDH1A1 1336/4885TSHR 3893/4885TYK2 4759/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.